News

Common insurance plans exclude NCI, NCCN cancer centers


 

Photo by Rhoda Baer

Cancer patient receiving chemotherapy

Narrow insurance plan coverage may prevent US cancer patients from receiving care at “high-quality” cancer centers, according to research published in the Journal of Clinical Oncology.

Researchers found that “narrow network” insurance plans—lower-premium plans with reduced access to certain providers—are more likely to exclude doctors associated with National Cancer Institute (NCI) and National Comprehensive Cancer Network (NCCN) cancer centers.

These centers are recognized for their scientific and research leadership, quality and safety initiatives, and access to expert physicians and clinical trials.

NCCN member institutions are particularly recognized for higher-quality care, and treatment at NCI-designated cancer centers is associated with lower mortality than other hospitals, particularly among more severely ill patients and those with more advanced disease.

For this study, researchers examined cancer provider networks offered on the 2014 individual health insurance exchanges and then determined which oncologists were affiliated with NCI-designated and NCCN cancer centers.

The researchers found that narrower networks were less likely to include physicians associated with NCI-designated and NCCN member institutions.

“To see such a robust result was surprising,” said study author Laura Yasaitis, PhD, of the University of Pennsylvania in Philadelphia.

“The finding that narrower networks were more likely to exclude NCI and NCCN oncologists was consistent no matter how we looked at it. This is not just a few networks. It’s a clear trend.”

The researchers said the results point to 2 major problems—transparency and access.

“Patients should be able to easily figure out whether the physicians they might need will be covered under a given plan,” said study author Justin E. Bekelman, MD, of the University of Pennsylvania.

The researchers suggested that insurers report doctor’s affiliations with NCI and NCCN cancer centers so that consumers can make more informed choices.

The team also suggested that insurers offer mechanisms that would allow patients to seek care out of network without incurring penalties in exceptional circumstances.

“If patients have narrow network plans and absolutely need the kind of complex cancer care that they can only receive from one of these providers, there should be a standard exception process to allow patients to access the care they need,” Dr Bekelman said.

Recommended Reading

Gilteritinib shows safety, efficacy in relapsed/refractory AML
MDedge Hematology and Oncology
Midostaurin improves survival in new AML
MDedge Hematology and Oncology
T receptor diversity may predict BCP-ALL response to blinatumomab
MDedge Hematology and Oncology
Telomere length predicts FCR response in CLL patients
MDedge Hematology and Oncology
NF-kB inhibitor IT-901 shows promise in Richter syndrome
MDedge Hematology and Oncology
Mapping the genomic landscape of T-ALL
MDedge Hematology and Oncology
FDA clears use of reagents to detect hematopoietic neoplasia
MDedge Hematology and Oncology
EC approves therapy for relapsed/refractory BCP-ALL
MDedge Hematology and Oncology
T-cell product improves outcomes of haplo-HSCT
MDedge Hematology and Oncology
CSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancer
MDedge Hematology and Oncology